Rembrandt Vision Technologies, L.P. v. Johnson & Johnson Vision Care, Inc.

300 F.R.D. 694, 2014 WL 3385039, 2014 U.S. Dist. LEXIS 93919
CourtDistrict Court, M.D. Florida
DecidedJuly 10, 2014
DocketNo. 3:11-cv-819-J-32-JRK
StatusPublished
Cited by3 cases

This text of 300 F.R.D. 694 (Rembrandt Vision Technologies, L.P. v. Johnson & Johnson Vision Care, Inc.) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Rembrandt Vision Technologies, L.P. v. Johnson & Johnson Vision Care, Inc., 300 F.R.D. 694, 2014 WL 3385039, 2014 U.S. Dist. LEXIS 93919 (M.D. Fla. 2014).

Opinion

ORDER

TIMOTHY J. CORRIGAN, District Judge.

Following a more than two-week trial in this contentious and expensive patent ease, the jury found for Defendant. During trial, one of Plaintiffs experts gave contradictory testimony, causing the Court to disallow it, a ruling which has now been affirmed on appeal. Post-trial it was found that one of Defendant’s expert witnesses also likely gave false trial testimony. How should the Court decide Plaintiffs Rule 60 motion seeking a new trial?

Plaintiff, Rembrandt Vision Technologies, L.P. (“Rembrandt”), asks the Court to order a new trial under Federal Rules of Civil Procedure 60(b)(2) and 60(b)(3) because of the alleged perjury of one of the expert witnesses for Defendant, Johnson & Johnson Vision Care, Inc. (“JJVC”), Dr. Christopher Bielawski. (Doc. 345 at 5-6).1 The Court has considered the voluminous filings, including Plaintiffs Motion to Set Aside the Judgment (Doc. 345), Defendant’s Response (Doe. 346), Plaintiffs Reply (Doc. 357), the various supplementary filings (Doe. 347, 348, 367, 377), Defendant’s Notice of New Authority (Doc. 370) and Plaintiffs Response (Doe. 372), as well as the parties’ statements regarding the effect of the Federal Circuit’s mandate (Doc. 379, 380) and updates regarding Dr. Bielawski’s status (Doe. 389, 390, 391, 392). The Court also heard extensive oral argument on August 2, 2013 (Doc. 373), the record of which is incorporated by reference.2

I. The Effect of the Federal Circuit’s Decision on the Rule 60 Motion

After the jury ruled in JJVC’s favor, Rembrandt filed a post-trial motion to reopen the case and compel discovery, questioning the veracity of the trial testimony of Dr. Bielawski. (Doc. 305). JJVC opposed the request (Doe. 308), and the Court denied the motion (Doc. 318). Thereafter, Rembrandt appealed the final judgment, which the Court entered in JJVC’s favor in accordance with the jury’s verdict and the Court’s alternative ruling granting JJVC’s Rule 50 motion based on the defective trial testimony of one of Rembrandt’s experts, Dr. Thomas Beebe. (Doc. 317). Although one of the grounds on appeal was this Court’s denial of Rembrandt’s motion to reopen discovery, the Federal Circuit did not reach that issue. Rembrandt Vision Technologies, L.P. v. Johnson & Johnson Vision Care, Inc., 725 F.3d 1377, 1380 n. 1 (Fed.Cir.2013). Rather, in affirming, the Federal Circuit only addressed the Court’s Rule 50 Order granting judgment as a matter of law based on the defects in Dr. Beebe’s testimony. Id.

The Court delayed ruling on this Rule 60 motion while the case was in the Federal Circuit. After the Federal Circuit mandate issued, the Court asked the parties what effect, if any, that mandate had on this Court’s consideration of the Rule 60 motion. (Doc. 378). Rembrandt, in essence, says the Federal Circuit decision has no effect and the Court should proceed on the merits. (Doc. 379). For a variety of reasons, but primarily because JJVC views the Federal Circuit af-firmance as being on an independent ground that renders the Rule 60 motion moot, JJVC says the Federal Circuit’s mandate, in and of itself, requires denial of the Rule 60 motion. (Doc. 380).

[698]*698While JJVC’s arguments have force, the Court is not convinced the Federal Circuit’s decision forecloses merits consideration of Rembrandt’s Rule 60 motion. If JJVC’s arguments on this score prove to be correct, the Court presumes that on appeal the Federal Circuit will so instruct and decline to reach the merits of the Rule 60 motion. In the meantime, this Court will address the merits.3

II. Dr. Bielawski’s Testimony

For the purposes of this motion, the Court assumes without deciding that Dr. Bielawski testified falsely when he said that he personally performed XPS and TOF-SIMS tests, and about his qualifications as an expert in performing those tests. In fact, even JJVC now agrees that there is clear and convincing evidence that Dr. Bielawski gave false testimony. (Doc. 380 at 18).4

This was a serious and detrimental occurrence. It insulted the jury, violated the integrity of the judicial process, and interfered with the search for the truth that is the hallmark of our trial-by-jury system. Moreover, this false testimony was given in a highly contested patent case in which an expert for Rembrandt, Dr. Beebe, radically changed his expert testimony during the middle of his examination. As a result, the Court struck his testimony and entered an alternative Rule 50 judgment against Rembrandt because it was unable to prove a required element of its ease without Dr. Beebe’s testimony. (Doc. 317). Now, having learned posNtrial that JJVC’s expert likely lied on the stand, arguably committing an act at least as egregious as Dr. Beebe’s, it is a fair question to ask whether Rembrandt should be entitled to a new trial.

However, that Dr. Bielawski testified falsely does not end the inquiry. In deciding what to do, the Court must be guided by the Federal Rules, which make it difficult to upset a jury’s verdict even if misconduct is shown. Thus, the Court turns to Rule 60 and looks at each of the sections cited by Rembrandt to determine whether a new trial is required. (Doc. 345 at 10-11).

A. Rule 60(b)(2)

“For the court to grant relief based upon newly discovered evidence under Rule 60(b)(2), a movant must meet a five-part test: (1) the evidence must be newly discovered since the trial; (2) due diligence on the part of the movant to discover the new evidence must be shown; (3) the evidence must not be merely cumulative or impeaching; (4) the evidence must be material; and (5) the evidence must be such that a new trial would probably produce a new result.” Waddell v. Hendry Cnty. Sheriff’s Office, 329 F.3d 1300, 1309 (11th Cir.2003); see also Scutieri v. Paige, 808 F.2d 785, 793 (11th Cir.1987).5 Since Rule 60(b)(2) relief is an extraordinary remedy, these requirements must be strictly met. Id. Without the need for further discussion, Rembrandt meets grounds 1 and 2.

Rembrandt asks this Court to set aside the judgment based on the newly discovered evidence that Dr. Bielawski lied about his qualifications and about performing tests. It is a very serious thing for a witness to lie from the stand. It can, in some cases bring criminal penalties for perjury. There is heightened concern here because Dr. Bielawski was a retained expert, solicited and sponsored by JJVC in a patent case in which expert testimony was critical.

Further, the matter that he lied about was material to his testimony. As Dr. Bielawski [699]*699was testifying about the results of the tests and how they were important to his opinions, whether he personally conducted them was an obviously relevant and material factor.

Regardless of the seriousness of Dr. Bielawski’s offense, however, Rembrandt still must demonstrate that a new trial would probably produce a different result.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
300 F.R.D. 694, 2014 WL 3385039, 2014 U.S. Dist. LEXIS 93919, Counsel Stack Legal Research, https://law.counselstack.com/opinion/rembrandt-vision-technologies-lp-v-johnson-johnson-vision-care-inc-flmd-2014.